CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).
- Citation:
- J Clin Oncol vol 32 (15_suppl) LBA3
- Meeting Instance:
- ASCO 2014
- Year:
- 2014
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2637
- Pharmas:
- Grants:
- Corr. Author:
- Alan P. Venook
- Authors:
- Alan P. Venook Donna Niedzwiecki Heinz-Josef Lenz Federico Innocenti Michelle R. Mahoney Bert H. O'Neil James Edward Shaw Blase N. Polite Howard S. Hochster James Norman Atkins Richard M. Goldberg Robert J. Mayer Richard L. Schilsky Monica M. Bertagnolli Charles David Blanke
- Networks:
- Study
- CALGB-80405
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: